Skip to main content
SpringerLink
Log in

Current Use of Domperidone and Co-prescribing of Medications that Increase Its Arrhythmogenic Potential Among Older Adults: A Population-Based Cohort Study in Ontario, Canada

  • Original Research Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Background and Objectives

Domperidone is commonly used to treat nausea and gastrointestinal disorders. Recent data suggests that it may increase the risk of sudden cardiac death, particularly in older people. Little is known about how it is used in contemporary practice. This study sought to characterize the population of older adults newly dispensed domperidone, describe dosages of domperidone used, and determine the frequency of co-prescribing domperidone with medications that may increase the arrhythmogenic potential of domperidone.

Methods

This is a retrospective cohort study using administrative health database information from Ontario, Canada. Prescription medication records were obtained from the Ontario Drug Benefit Claims Database. Diagnostic codes were obtained from the Ontario Health Insurance Plan Database, the Canadian Institute for Health Information Discharge Abstract Database, and the same-day surgery database. Patients who received a new prescription for domperidone between April 1, 2003 and March 31, 2010 were included.

Results

A total of 122,233 patients met inclusion criteria; 85 % were between 66 and 84 years old and 63 % were female. The mean estimated daily domperidone dose was 35 mg, and the estimated daily dose was <40 mg for 62 % of users. Strong or moderately strong cytochrome P-450 (CYP) 3A4 inhibitors were co-prescribed for 4.3 and 10.7 % of users, while medications with a known risk or possible risk for torsades de pointes (TdP) were co-prescribed to 18.3 and 18.8 % of users.

Conclusions

Older domperidone users were commonly co-prescribed drugs with the potential to increase the risk for TdP. These combinations should be avoided, as iatrogenic QT prolongation is a modifiable risk factor for TdP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Barone JA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother. 1999;33(4):429–40.

    Article  PubMed  CAS  Google Scholar 

  2. Champion MC, Hartnett M, Yen M. Domperidone, a new dopamine antagonist. CMAJ. 1986;135(5):457–61.

    PubMed  CAS  PubMed Central  Google Scholar 

  3. Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol. 2007;102(9):2036–45.

    Article  PubMed  CAS  Google Scholar 

  4. Grimes D, Gordon J, Snelgrove B, et al. Canadian guidelines on parkinson’s disease. Can J Neurol Sci. 2012;39(4 Suppl 4):S1–30.

    PubMed  Google Scholar 

  5. Mathivanan M. Association of domperidone maleate with serious abnormal heart rhythms and sudden death (cardiac arrest). Health Canada Public Communication Web site. http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2012/14118a-eng.php. Published 2012. Accessed 5 May 2014.

  6. Johannes CB, Varas-Lorenzo C, McQuay LJ, Midkiff KD, Fife D. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case–control study. Pharmacoepidemiol Drug Saf. 2010;19(9):881–8.

    Article  PubMed  Google Scholar 

  7. van Noord C, Dieleman JP, van Herpen G, Verhamme K, Sturkenboom MC. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case–control study in the Netherlands. Drug Saf. 2010;33(11):1003–14.

    Article  PubMed  Google Scholar 

  8. Levy AR, O’Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario drug benefit database. Can J Clin Pharmacol. 2003;10(2):67–71.

    PubMed  Google Scholar 

  9. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care. 2002;25(3):512–6.

    Article  PubMed  Google Scholar 

  10. Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying individuals with physician diagnosed COPD in health administrative databases. COPD. 2009;6(5):388–94.

    Article  PubMed  CAS  Google Scholar 

  11. Schultz SE, Rothwell DM, Chen Z, Tu K. Identifying cases of congestive heart failure from administrative data: a validation study using primary care patient records. Chronic Dis Inj Can. 2013;33(3):160–6.

    PubMed  CAS  Google Scholar 

  12. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013–22.

    Article  PubMed  CAS  Google Scholar 

  13. Roden DM. Cellular basis of drug-induced torsades de pointes. Br J Pharmacol. 2008;154(7):1502–7.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol. 2005;26(5):720–3.

    Article  PubMed  CAS  Google Scholar 

  15. Boyce MJ, Baisley KJ, Warrington SJ. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. Br J Clin Pharmacol. 2012;73(3):411–21.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Combined list of all QTdrugs and the list of drugs to avoid for patients with congenital long QT syndrome. Credible Meds Web site. https://www.crediblemeds.org/everyone/composite-list-all-qtdrugs/. Updated 2014. Accessed 8 July 2014.

  17. Hondeghem LM. Domperidone: Limited benefits with significant risk for sudden cardiac death. J Cardiovasc Pharmacol. 2013;61(3):218–25.

    Article  PubMed  CAS  Google Scholar 

  18. Tsujikawa K, Dan Y, Nogawa K, et al. Potentiation of domperidone-induced catalepsy by a P-glycoprotein inhibitor, cyclosporin A. Biopharm Drug Dispos. 2003;24(3):105–14.

    Article  PubMed  CAS  Google Scholar 

  19. Flockhart D. Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine (2007) Web site. http://medicine.iupui.edu/clinpharm/ddis/clinical-table/. Accessed 5 May 2014.

  20. Penzak SR. Infectious disease: drug interactions in infectious diseases. In: Piscitelli SC, Rodvold KA, editors. Infectious disease: drug interactions in infectious diseases. 2nd ed. Totowa: Humana Press Inc.; 2005. p. 41.

    Google Scholar 

  21. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–51.

    Article  PubMed  CAS  Google Scholar 

  22. Newton-Cheh C, Eijgelsheim M, Rice KM, et al. Common variants at ten loci influence QT interval duration in the QTGEN study. Nat Genet. 2009;41(4):399–406.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  23. CMDh confirms recommendations on restricting use of domperidone-containing medicines: European commission to take final legal decision. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/04/WC500165651.pdf. Published 25 April 2014. Updated 2014. Accessed 5 May 2014.

  24. Compendium of Pharmaceuticals and Specialities. Domperidone: upper gastrointestinal motility modifier. 2014th ed. Toronto: Canadian Pharmacists Association; 2009.

    Google Scholar 

  25. Lazzara R. Amiodarone and torsade de pointes. Ann Intern Med. 1989;111(7):549–51.

    Article  PubMed  CAS  Google Scholar 

  26. Duan JJ, Ma JH, Zhang PH, Wang XP, Zou AR, Tu DN. Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 transmembrane domain. Acta Pharmacol Sin. 2007;28(7):959–67.

    Article  PubMed  CAS  Google Scholar 

  27. Park SJ, Kim KS, Kim EJ. Blockade of HERG K+ channel by an antihistamine drug brompheniramine requires the channel binding within the S6 residue Y652 and F656. J Appl Toxicol. 2008;28(2):104–11.

    Article  PubMed  CAS  Google Scholar 

  28. Michaud V, Turgeon J. Domperidone and sudden cardiac death: how much longer should we wait? J Cardiovasc Pharmacol. 2013;61(3):215–7.

    Article  PubMed  CAS  Google Scholar 

  29. Ahmad N, Keith-Ferris J, Gooden E, Abell T. Making a case for domperidone in the treatment of gastrointestinal motility disorders. Curr Opin Pharmacol. 2006;6(6):571–6.

    Article  PubMed  CAS  Google Scholar 

  30. Malek NM, Grosset KA, Stewart D, Macphee GJ, Grosset DG. Prescription of drugs with potential adverse effects on cardiac conduction in parkinson’s disease. Parkinsonism Relat Disord. 2013;19(6):586–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred.

This study was funded by a Team Grant (OTG-88591) from the Canadian Institutes of Health Research Institute of Nutrition, Metabolism and Diabetes.

Douglas S. Lee was supported by a CIHR clinician-scientist award. We thank Brogan Inc., Ottawa for use of their Drug Product and Therapeutic Class Database.

Author information

Authors and Affiliations

  1. Schlegel Research Chair in Geriatric Pharmacotherapy, Schlegel-UW Research Institute for Ageing, University of Waterloo, 10 Victoria St S, Room 7004, Kitchener, ON, N2G 1C5, Canada

    Carlos Rojas-Fernandez

  2. School of Pharmacy, University of Waterloo, 10 Victoria St S, Room 7004, Kitchener, ON, N2G 1C5, Canada

    Carlos Rojas-Fernandez

  3. School of Public Health and Health Systems, University of Waterloo, 10 Victoria St S, Room 7004, Kitchener, ON, N2G 1C5, Canada

    Carlos Rojas-Fernandez

  4. Department of Family Medicine, McMaster University School of Medicine, 10 Victoria St S, Room 7004, Kitchener, ON, N2G 1C5, Canada

    Carlos Rojas-Fernandez

  5. Division of Respirology, St. Michael’s Hospital, Li Ka Shing Knowledge Institute, Department of Medicine, University of Toronto, 30 Bond Street, 6th Floor, Bond Wing, Toronto, ON, M5B 1W8, Canada

    Anne L. Stephenson

  6. Institute for Clinical Evaluative Sciences, Rm G1 06, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada

    Hadas D. Fischer, Xuesong Wang, Douglas S. Lee & Paula A. Rochon

  7. Parkinson’s Disease and Movement Disorders Clinic, Division of Neurology, Department of Medicine, University of Ottawa, The Ottawa Hospital, Ottawa, Canada

    Tiago Mestre

  8. The Ottawa Hospital-Civic Campus, 1053 Carling Ave., Floor C2, Room 2244, Ottawa, ON, K1Y 4E9, Canada

    Tiago Mestre

  9. Division of Clinical Pharmacology and Toxicology, Hospital for Sick Children, 555 University Ave, Toronto, ON, M5G 1X8, Canada

    Janine R. Hutson

  10. Toronto Western Hospital Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson’s Disease, UHN and University of Toronto, 399 Bathurst St, Toronto, ON, M5T 2S8, Canada

    Margarita Pondal

  11. Peter Munk Cardiac Centre and Joint Department of Medical Imaging, University Health Network and University of Toronto, Toronto, Canada

    Douglas S. Lee

  12. Women’s College Research Institute, Women’s College Hospital, 790 Bay Street, Toronto, M5G 1N8, Canada

    Paula A. Rochon

  13. Department of Medicine, Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada

    Paula A. Rochon

  14. Toronto Western Hospital Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson’s Disease, University of Toronto, 7McL, 399 Bathurst ST., Toronto, ON, M5T 2S8, Canada

    Connie Marras

Authors
  1. Carlos Rojas-Fernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne L. Stephenson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hadas D. Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xuesong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tiago Mestre
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Janine R. Hutson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Margarita Pondal
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Douglas S. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Paula A. Rochon
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Connie Marras
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlos Rojas-Fernandez.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rojas-Fernandez, C., Stephenson, A.L., Fischer, H.D. et al. Current Use of Domperidone and Co-prescribing of Medications that Increase Its Arrhythmogenic Potential Among Older Adults: A Population-Based Cohort Study in Ontario, Canada. Drugs Aging 31, 805–813 (2014). https://doi.org/10.1007/s40266-014-0215-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-014-0215-z

Keywords

Search

Navigation